Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

[1]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[2]  E. Jonasch,et al.  Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. , 2001, The oncologist.

[3]  M. Reindl,et al.  A comparative study of the relative bioavailability of different interferon beta preparations , 2000, Neurology.

[4]  G. Zhao,et al.  Effect of interferon β-1b in MS , 2000, Neurology.

[5]  M. Reindl,et al.  Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies , 1999, Neurology.

[6]  D. Paty,et al.  The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b , 1999, Neurology.

[7]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[8]  G. Williams,et al.  Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[9]  M. Reindl,et al.  Bioavailability of beta interferon 1b in MS patients with and without neutralising antibodies , 1998, Journal of Neuroimmunology.

[10]  C. Pozzilli,et al.  Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a , 1998 .

[11]  J. Petkau,et al.  Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis , 1997, Multiple sclerosis.

[12]  Cindy Farquhar,et al.  3 The Cochrane Library , 1996 .

[13]  L. Wilkins.  Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b , 1996, Neurology.

[14]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[15]  M. Horsfield,et al.  Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis. A comparison of techniques. , 1995, Brain : a journal of neurology.

[16]  L. Hedges,et al.  The Handbook of Research Synthesis , 1995 .

[17]  P. S. Albert,et al.  Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis , 1995, Neurology.

[18]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[19]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[20]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[21]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[22]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[23]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[24]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[25]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[26]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[27]  H. Ovadia,et al.  Frontiers in multiple sclerosis : clinical research and therapy , 1997 .

[28]  R. Rosenthal.  Parametric measures of effect size. , 1994 .